

**Sun Pharmaceutical Industries Limited**  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



January 16, 2024

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

**Sub: Press Release**

We are pleased to enclose herewith our Press Release relating to Earnings Call for financial results for the third quarter ending December 31, 2023, which we shall be releasing after sending this letter to you.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



**FOR IMMEDIATE RELEASE**

## **Sun Pharma to announce third quarter results on January 31, 2024**

January 16, 2024, Mumbai: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) will announce results for the third quarter ending December 31, 2023 on January 31, 2024. These results will also be available on the Company website, [www.sunpharma.com](http://www.sunpharma.com).

### **Earnings call (06.30 pm IST, January 31, 2024)**

The Company will conduct an hour-long call at 06.30 pm IST on January 31, 2024 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please pre-register yourself on below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, [www.sunpharma.com](http://www.sunpharma.com). A transcript of this conference call will also be available on the website.

### **Summary of events**

<b>Event</b>	<b>Date and time</b>	<b>Telephone number/ website</b>
Earnings release	January 31, 2024	<a href="http://www.sunpharma.com">www.sunpharma.com</a>
Earnings conference call	06.30 pm IST, January 31, 2024	Universal Number: +91 22 6629 0049 +91 22 7194 5729  Via audio webcast, details of which will be made available on <a href="http://www.sunpharma.com">www.sunpharma.com</a>
Pre-registration details (to avoid wait time)		Click here for <a href="#">DiamondPassRegistration</a>

### **Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Sun Pharmaceutical Industries Limited  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



**About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):**

Sun Pharma is the world's fourth largest specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on "X" @SunPharma\_Live

**Contacts:**

**Investors:**

Dr. Abhishek Sharma  
Tel +91 22 4324 4324, Xtn 2929  
Tel Direct +91 22 4324 2929  
Mobile +91 98196 86016  
E mail [abhi.sharma@sunpharma.com](mailto:abhi.sharma@sunpharma.com)

**Media:**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E mail [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)